TY - JOUR
T1 - Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis
AU - Graziadei, Ivo W.
AU - Wiesner, Russell H.
AU - Marotta, Paul J.
AU - Porayko, Michael K.
AU - Eileen Hay, J.
AU - Charlton, Michael R.
AU - Poterucha, John J.
AU - Rosen, Charles B.
AU - Gores, Gregory J.
AU - LaRusso, Nicholas E.
AU - Krom, Ruud A.F.
PY - 1999
Y1 - 1999
N2 - Liver transplantation is the only effective therapeutic option for patients with end-stage liver disease due to primary sclerosing cholangitis (PSC). In this study, we analyzed a single center's experience with 150 consecutive PSC patients who received 174 liver allografts. Mean follow-up was 55 months. Actuarial patient survival at 1, 2, 5, and 10 years was 93.7%, 92.2%, 86.4%, and 69.8%, respectively, whereas graft survival was 83.4%, 83.4%, 79.0%, and 60.5%, respectively. The main indication for retransplantation was hepatic artery thrombosis, and the major cause of death was severe infection. Patients with PSC had a higher incidence of acute cellular and chronic ductopenic rejection compared to a non-PSC control group. Chronic ductopenic rejection adversely affected patient and graft survival. Biliary strictures, both anastomotic and nonanastomotic, were frequent and occurred in 16.2% and 27.2% of patients, respectively. The incidence of recurrent PSC was 20%. A negative impact on patient survival was not seen in patients with either postoperative biliary strictures or recurrence of PSC. Six patients (4%) had cholangiocarcinoma and 1 patient died related to recurrence of malignant disease. Seventy-eight percent of PSC patients had associated inflammatory bowel disease, most commonly chronic ulcerative colitis, which did not adversely impact patient outcome posttransplantation. Nine patients required procto-colectomy after liver transplantation; 5 because of intractable symptoms related to inflammatory bowel disease and 4 due to the development of colorectal carcinoma/highgrade dysplasia. Our data show that liver transplantation provides excellent long- term patient and graft survival for patients with end-stage PSC.
AB - Liver transplantation is the only effective therapeutic option for patients with end-stage liver disease due to primary sclerosing cholangitis (PSC). In this study, we analyzed a single center's experience with 150 consecutive PSC patients who received 174 liver allografts. Mean follow-up was 55 months. Actuarial patient survival at 1, 2, 5, and 10 years was 93.7%, 92.2%, 86.4%, and 69.8%, respectively, whereas graft survival was 83.4%, 83.4%, 79.0%, and 60.5%, respectively. The main indication for retransplantation was hepatic artery thrombosis, and the major cause of death was severe infection. Patients with PSC had a higher incidence of acute cellular and chronic ductopenic rejection compared to a non-PSC control group. Chronic ductopenic rejection adversely affected patient and graft survival. Biliary strictures, both anastomotic and nonanastomotic, were frequent and occurred in 16.2% and 27.2% of patients, respectively. The incidence of recurrent PSC was 20%. A negative impact on patient survival was not seen in patients with either postoperative biliary strictures or recurrence of PSC. Six patients (4%) had cholangiocarcinoma and 1 patient died related to recurrence of malignant disease. Seventy-eight percent of PSC patients had associated inflammatory bowel disease, most commonly chronic ulcerative colitis, which did not adversely impact patient outcome posttransplantation. Nine patients required procto-colectomy after liver transplantation; 5 because of intractable symptoms related to inflammatory bowel disease and 4 due to the development of colorectal carcinoma/highgrade dysplasia. Our data show that liver transplantation provides excellent long- term patient and graft survival for patients with end-stage PSC.
UR - http://www.scopus.com/inward/record.url?scp=0032734346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032734346&partnerID=8YFLogxK
U2 - 10.1002/hep.510300501
DO - 10.1002/hep.510300501
M3 - Article
C2 - 10534330
AN - SCOPUS:0032734346
SN - 0270-9139
VL - 30
SP - 1121
EP - 1127
JO - Hepatology
JF - Hepatology
IS - 5
ER -